Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS

Immunol Today. 1999 Feb;20(2):66-71. doi: 10.1016/s0167-5699(98)01392-9.

Abstract

Recent studies have demonstrated protective effects of alloimmunization in the SIV model. Here, Gene Shearer, Ligia Pinto and Mario Clerici raise the possibility that alloimmunization against a spectrum of HLA-disparate leukocytes be considered for immune-based therapy and as an AIDS vaccine.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • AIDS Vaccines / therapeutic use
  • Acquired Immunodeficiency Syndrome / prevention & control*
  • Animals
  • Antigen Presentation
  • CD8-Positive T-Lymphocytes / immunology
  • Disease Progression
  • Drug Design
  • Gene Products, env / immunology
  • HIV Antigens / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV Infections / therapy*
  • HIV-1 / immunology
  • HLA Antigens / genetics
  • HLA Antigens / immunology*
  • Humans
  • Immunity, Innate
  • Immunization*
  • Leukocytes / immunology*
  • Macaca / immunology
  • Mice
  • Molecular Mimicry
  • Rats
  • Simian Acquired Immunodeficiency Syndrome / prevention & control
  • Simian Acquired Immunodeficiency Syndrome / therapy
  • Simian Immunodeficiency Virus / immunology
  • Th2 Cells / immunology
  • Virion / immunology

Substances

  • AIDS Vaccines
  • Gene Products, env
  • HIV Antigens
  • HLA Antigens